z-logo
Premium
SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY
Author(s) -
Palomba M.L.,
Cartron G.,
Popplewell L.,
Ribrag V.,
Westin J.,
Chitra S.,
Huw L.,
Newberry K.,
Raval A.,
Xu J.,
Morschhauser F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.203_2631
Subject(s) - medicine , tolerability , neutropenia , gastroenterology , refractory (planetary science) , diffuse large b cell lymphoma , oncology , surgery , adverse effect , lymphoma , toxicity , physics , astrobiology

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom